Clinical trial
Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With…
NCT00179608 · Celgene, Industry · Completed
Key facts
| NCT number | NCT00179608 |
|---|---|
| Title | Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy |
| Official title | Phase I Safety Study of the Combination of Lenalidomide and DTIC (Dacarbazine) in Patients With Metastatic Malignant Melanoma Previously Untreated With Systemic Chemotherapy |
| Lead sponsor | Celgene, Industry |
| Collaborators | Prologue Research International Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malignant Melanoma |
| Intervention type | Drug |
| Interventions | CC-5013 |
| Enrollment | 28 |
| Start date | Sep 1, 2005 |
| Primary completion | Jun 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Sep 16, 2005 |
| Last update posted | Nov 8, 2019 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: